stockrow
Friday 6 November 2026
Export BCLI’s income statement to Excel — free account
Brainstorm Cell Therapeutics Inc.
BCLI Healthcare Biotechnology
- EPS
- −2.94%
- Free cash flow
- +74.4%
- Total debt
- +1,148.5%
Quarter to June 2026, against a year earlier
0.90
0.04
+4.65%
Follow BCLI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 33 | 33 | 33 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) | (11) | +8.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (5) | (5) | (14) | (23) | (32) | (24) | (24) | (17) | (12) | (10) | (11) | +8.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (4.05) | (3.90) | (10.49) | (15.89) | (16.04) | (10.19) | (9.90) | (6.00) | (2.31) | (1.11) | (0.93) | (13.4%) | ||||||
| Cash flow | (4.71) | (1.89) | (9.29) | (7.70) | (17.68) | (10.88) | (7.93) | (7.12) | (1.81) | (0.75) | (0.37) | (18.4%) | ||||||
| Capex | (0.08) | (0.14) | (0.28) | (0.32) | (0.19) | (0.14) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (4.79) | (2.03) | (9.56) | (8.02) | (17.87) | (11.02) | (7.95) | (7.13) | (1.81) | (0.75) | (0.37) | (18.6%) | ||||||
| Book value | 7.95 | 4.70 | 3.76 | (8.37) | 17.81 | 8.01 | (1.24) | (1.69) | (1.55) | (1.08) | (1.05) | n/m | ||||||
| Shares, m | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 9 | 11 | +25.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (2) | (12) | (11) | (35) | (26) | (19) | (20) | (9) | (7) | (4) | +2.0% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | n/m | ||||||
| Free cash flow | (6) | (3) | (13) | (12) | (36) | (27) | (19) | (20) | (9) | (7) | (4) | +1.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 10 | 4 | 4 | (14) | 32 | 17 | (6) | (6) | (9) | (11) | (12) | n/m | |||||
| Net debt | (10) | (8) | (7) | 1 | (39) | (21) | (2) | (1) | 0 | 1 | 1 | n/m | ||||||
| Shareholders’ equity | 10 | 6 | 5 | (12) | 35 | 19 | (3) | (5) | (8) | (10) | (12) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (35.78) | (44.63) | (123.16) | (261.83) | (110.09) | (60.74) | (128.69) | (271.62) | (384.87) | (722.28) | (627.43) | (686.5) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (41.46) | (62.76) | (256.02) | 645.29 | (273.75) | (89.25) | (297.38) | 436.73 | 184.17 | 116.14 | 119.20 | +157.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 22 | 24 | 31 | 32 | 40 | 43 | 43 | 29 | 27 | 20 | — | (1.1%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Brainstorm Cell Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VTGN VistaGen Therapeutics, Inc. | $7.3M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| SNGX Soligenix Inc. | $7.3M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $7.3M | — (loss-making) | — | −39.32% (below 0%: shrinking) | 0.00% | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $7.0M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | |
| IMRN IMMURON | $6.9M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $6.6M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $7.1M | — | — | −39.32% | — | +32.67% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 16 May 2025
Ownership
Directors and executive officers, together
11.15%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement